Table 1 from Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases. | Semantic Scholar (2024)

An overview of what is currently known about A. muciniphila’s phenotypical and genotypic traits, as well as its culture techniques and its connections to a number of human diseases and its potential application as an effective next generation probiotic is provided.

Akkermansia muciniphila specializes in the degradation of mucin and uses the mucin as the sole source of carbon and nitrogen and has important regulatory effects on gut homeostasis.

The current knowledge of the role of A. muciniphila in IBD is summarised, especially focusing on the related mechanisms, as well as the strategies based on supplementation with A. cocci-targeted and -based therapies in the treatment of inflammatory bowel disease.

The present review discusses and summarizes the role of A. muciniphila in diabetes mellitus type 2, obesity, nonalcoholic fatty liver disease and other metabolic disorders.

This review aims to summarize the current knowledge of how Akkermansia muciniphila interacts with the host and influences host metabolic homeostasis and disease progression and identify preventive and/or therapeutic solutions targeting gut–liver–brain axes for multiple diseases via Akker mansia muc iniphila.

A mixture of vegetable fibers and fructo-oligosaccharides is proposed as a valid alternative with limited side effects and shows that it regenerates the populations of A. muciniphila and restores beneficial intestinal microflora.

The differential impacts of Uro-A and B on the gut microbiota composition in normal rats would serve as a guide in the choice of these metabolites as a functional food ingredient or prebiotic.

Intranasal irrigation of live L. lactis W136 bacteria to patients with refractory chronic rhinosinusitis was safe, and was associated with effects on symptoms, mucosal aspect and microbiome composition, which may find a role as a treatment strategy for CRS.

The paper reviewed the specific effects and mechanisms of probiotics in metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM) and hypertension, and found that probiotics protected pancreatic islet cells, improved insulin sensitivity and accelerated glucose transport.

The aim of this study is to clarify the therapeutic characteristics of berberine further and provide the theoretical basis for the regulation of metabolic disorder from the perspective of gut microbiota.

...

...

The A. muciniphila case can be seen as a model for the comprehensive safety evaluations required by the European authorities and many of the criteria required for novel food safety assessment in Europe can be fulfilled.

The results demonstrate that A. muciniphila adheres to the intestinal epithelium and strengthens enterocyte monolayer integrity in vitro, suggesting an ability to fortify an impaired gut barrier.

It is shown that A. muciniphila retains its efficacy when grown on a synthetic medium compatible with human administration and enhanced its capacity to reduce fat mass development, insulin resistance and dyslipidemia in mice, and Amuc_1100, a specific protein isolated from the outer membrane of A. Sydneyi, interacts with Toll-like receptor 2, is stable at temperatures used for pasteurization and partly recapitulates the beneficial effects of the bacterium.

The data suggest that patients with ALD might benefit from A. muciniphila supplementation, which promotes intestinal barrier integrity and ameliorates experimental ALD.

Results indicate that outer membrane protein composition and particularly the newly identified highly abundant pili-like protein Amuc_1100 of A. muciniphila are involved in host immunological homeostasis at the gut mucosa, and improvement of gut barrier function.

Substantial insight is provided into the intricate mechanisms of bacterial regulation of the cross-talk between the host and gut microbiota and provides a rationale for the development of a treatment that uses this human mucus colonizer for the prevention or treatment of obesity and its associated metabolic disorders.

Results imply that AmEVs may act as a functional moiety for controlling gut permeability and that the regulation of intestinal barrier integrity can improve metabolic functions in HFD-fed mice.

The early postnatal period is a critical time for microbial protection from type 1 diabetes and it is suggested that the mucolytic bacterium A. muciniphila plays a protective role in autoimmune diabetes development, particularly during infancy.

Transfer of the whole microbiota may not reduceabetes incidence despite a major change in gut microbiota, but single symbionts such as A. muciniphila with beneficial metabolic and immune signalling effects may reduce diabetes incidence when administered as a probiotic.

In vitro pretreatment of A. muciniphila-derived EV ameliorated the production of a pro-inflammatory cytokine IL-6 from colon epithelial cells induced by Escherichia coli EV, and protected DSS-induced IBD phenotypes, such as body weight loss, colon length, and inflammatory cell infiltration of colon wall.

...

...